Sunday, June 16, 2013

Bristol-Myers collaboarate with Simcere Pharmaceuticals for development and commercialization of subcutaneous formulation of Bristol-Myer Squibb's RA drug Orencia

BMY and Simcere pharmaceuticals have agreed to collaborate in China on the development and commercialization of the subcutaneous (SC) formulation of Bristol-Myers Squibb's biologic medicine, Orencia® (abatacept), for the treatment of rheumatoid arthritis. Orencia SC is already on the market for the treatment of rheumatoid arthritis in the U.S., Europe and Japan.
Under the terms of the agreement, Simcere will perform and fund all development and regulatory activities required to obtain market approval for Orencia SC in China, based on a pre-agreed development plan. The companies will share responsibility for commercializing Orencia, and will share profits and losses related to Orencia SC in China. Financial terms were not disclosed.   

No comments:

Post a Comment